$Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation$

Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Information regarding the curative role of allogeneic stem cell transplantation (allo-HCT) in systemic anaplastic large cell lymphoma (sALCL) is scarce. We analyzed the results of allo-HCT in patients with relapsed/refractory sALCL with special emphasis on the role of brentuximab vedotin (BV) as a b...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bone marrow transplantation (Basingstoke) 2020-03, Vol.55 (3), p.633-640
Hauptverfasser:	Domingo-Domènech, E., Boumendil, A., Climent, F., Socié, G., Kroschinsky, F., Finel, H., Vandenbergue, E., Nemet, D., Stelljes, M., Bittenbring, J. T., Robinson, S., Montoto, S., Sureda, A., Dreger, P.
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/1990/291/1621/1916 692/699/1541/1990/291/1621/1916 Anaplastic large-cell lymphoma Brentuximab vedotin Cancer Care and treatment Cell Biology Females Hematology Hematopoietic stem cells Internal Medicine Lymphoma Medicine Medicine & Public Health Methods Monoclonal antibodies Non-Hodgkin's lymphomas Patient outcomes Public Health Relapse Remission Stem cell transplantation Stem Cells Survival Targeted cancer therapy Transplantation Transplants & implants
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!